Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

NCT00071396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Campath-1H
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]